Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073605 | 1.00 | HTT (0.36) | HTTHSD17B10USP2GAACACNA1G | |
| SCHEMBL7075839 | 0.97 | HTT (0.36) | HTTHSD17B10USP2GAACACNA1G | |
| SCHEMBL7075842 | 0.97 | HTT (0.36) | HTTHSD17B10USP2GAACACNA1G | |
| SCHEMBL7071181 | 0.93 | HSD17B10 (0.38) | HTTHSD17B10USP2GAA | |
| SCHEMBL7071178 | 0.93 | HSD17B10 (0.38) | HTTHSD17B10USP2GAA | |
| SCHEMBL7077487 | 0.87 | USP2 (0.32) | HTTHSD17B10USP2GAA | |
| SCHEMBL7072109 | 0.87 | USP2 (0.32) | HTTHSD17B10USP2GAA | |
| Trifluoroacetic Acid SCHEMBL7075182 | 0.87 | HTT (0.34) | HTTHSD17B10USP2GAA | |
| Trifluoroacetic Acid SCHEMBL7075185 | 0.87 | HTT (0.34) | HTTHSD17B10USP2GAA | |
| SCHEMBL7073127 | 0.86 | USP2 (0.34) | HTTHSD17B10USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | HTT 4867/4885HSD17B10 3835/4885USP2 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.